MedTrace Logo

Anti-thrombotic Monotherapy With the HeartMate 3 LVAS

NCT03704220 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-08-04

No results posted yet for this study

Summary

The purpose of this study is to obtain a single-center safety and feasibility data on patients managed with a single anti-thrombotic therapy and the incidence of thrombotic adverse events associated with HeartMate 3 LVAS therapy.

Conditions

Interventions

DRUG

Warfarin

Removal of anticoagulation with warfarin

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Institute for Clinical and Experimental Medicine

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-16
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03704220 on ClinicalTrials.gov